Tivic Health Receives Approval to Sell 8.44M Common Shares by Selling Shareholders
ByAinvest
Friday, Jun 6, 2025 4:45 pm ET1min read
MBRX--
The amended registration statement indicates that the company is offering the securities on a reasonable best efforts basis. The securities are expected to be issued in a single closing, and the combined public offering price per share of common stock or pre-funded warrant and accompanying common warrant will be fixed for the duration of this offering. Moleculin Biotech has engaged Roth Capital Partners, LLC as its sole placement agent for the offering [1].
The company's common stock is listed on the Nasdaq Capital Market under the symbol "MBRX." As of June 5, 2025, the last reported sale price of the common stock on Nasdaq was $0.69 per share. The actual number of securities, the combined offering price per share of common stock or pre-funded warrant and accompanying common warrant, and the exercise price per share of common stock for the accompanying common warrants will be determined based on market conditions at the time of pricing [1].
The filing also includes information about the company's corporate structure, executive officers, and legal counsel. The company's chief executive officer and chairman is Walter V. Klemp, and the company's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, Texas 77007 [1].
References:
[1] https://quantisnow.com/insight/amendment-sec-form-s1a-filed-by-moleculin-biotech-inc-6075729
TIVC--
Tivic Health has filed a prospectus to resale 8.44M shares of common stock by selling shareholders. The company will not receive any proceeds from the sale. The prospectus is not an offer to sell.
Moleculin Biotech, Inc., a biotechnology company based in Houston, Texas, has filed an amended Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC). The filing, dated June 6, 2025, includes details about the company's planned sale of up to 10,869,565 shares of common stock and up to 32,608,696 accompanying Series E warrants to purchase shares of common stock [1].The amended registration statement indicates that the company is offering the securities on a reasonable best efforts basis. The securities are expected to be issued in a single closing, and the combined public offering price per share of common stock or pre-funded warrant and accompanying common warrant will be fixed for the duration of this offering. Moleculin Biotech has engaged Roth Capital Partners, LLC as its sole placement agent for the offering [1].
The company's common stock is listed on the Nasdaq Capital Market under the symbol "MBRX." As of June 5, 2025, the last reported sale price of the common stock on Nasdaq was $0.69 per share. The actual number of securities, the combined offering price per share of common stock or pre-funded warrant and accompanying common warrant, and the exercise price per share of common stock for the accompanying common warrants will be determined based on market conditions at the time of pricing [1].
The filing also includes information about the company's corporate structure, executive officers, and legal counsel. The company's chief executive officer and chairman is Walter V. Klemp, and the company's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, Texas 77007 [1].
References:
[1] https://quantisnow.com/insight/amendment-sec-form-s1a-filed-by-moleculin-biotech-inc-6075729

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet